Status:
NOT_YET_RECRUITING
Establishing Radiolabelled PSMA as a Target for Glioma Treatment
Lead Sponsor:
King's College Hospital NHS Trust
Collaborating Sponsors:
King's College London
Conditions:
Glioma, Malignant
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
A study is being performed to observe whether a novel type of brain imaging using a technique called PET-MRI may provide useful information in the 'mapping' of adult primary brain tumours. It employs ...
Detailed Description
One potential avenue of high grade glioma treatment involves a 'theranostic' radiotherapeutic approach. This consists of two stages: firstly, a particular protein expressed specifically by the tumour ...
Eligibility Criteria
Inclusion
- Individuals of 18 years or older
- Referred for surgery (resection or biopsy) of presumed high grade primary brain tumour (based on imaging features of aggression e.g. perfusion imaging, diffusion restriction etc.). As standard, all patients will have had a full body CT and other investigations to rule out metastatic disease (this has a very high negative predictive value).
- Written informed consent
Exclusion
- Patient already enrolled in a drug trial
- Contra-indication for MRI contrast
- Contra-indication for radiotracer
- Inability to give consent
- Patient is pregnant or planning to become pregnant
Key Trial Info
Start Date :
August 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2027
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05263466
Start Date
August 1 2022
End Date
May 1 2027
Last Update
June 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
King's College London
London, United Kingdom